Medical outcomes of children with neurodevelopmental disorders after SARS-CoV-2 vaccination: A six-month follow-up study

INTRODUCTION: The BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna) vaccines have been approved for children and adolescents for protecting against SARS-CoV-2 infection. This longitudinal study aimed to compare adverse outcomes after SARS-CoV-2 vaccination in children with neurodevelopmental disord...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Liang-Jen, Tsai, Ching-Shu, Chou, Wen-Jiun, Li, Chia-Jung, Lee, Sheng-Yu, Chen, Yi-Chun, Lin, I-Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225977/
https://www.ncbi.nlm.nih.gov/pubmed/37271705
http://dx.doi.org/10.1016/j.vaccine.2023.05.067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225977/
https://www.ncbi.nlm.nih.gov/pubmed/37271705
http://dx.doi.org/10.1016/j.vaccine.2023.05.067

Ejemplares similares